Provided by Tiger Trade Technology Pte. Ltd.

ImmunityBio, Inc.

7.38
0.0000
Post-market: 7.30-0.0792-1.07%19:59 EDT
Volume:14.46M
Turnover:107.51M
Market Cap:7.59B
PE:-19.32
High:7.65
Open:7.37
Low:7.13
Close:7.38
52wk High:12.43
52wk Low:1.83
Shares:1.03B
Float Shares:336.00M
Volume Ratio:0.36
T/O Rate:4.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3820
EPS(LYR):-0.3820
ROE:78.05%
ROA:-36.17%
PB:-15.16
PE(LYR):-19.32

Loading ...

Why Is ImmunityBio Stock Soaring On Friday?

Benzinga_recent_news
·
Mar 13

ImmunityBio reports scalable cryopreserved NK cell production reaching 5 billion cells per apheresis

Reuters
·
Mar 13

ImmunityBio completes Phase 1 QUILT-3.076 trial of M-ceNK plus ANKTIVA in 10 patients

Reuters
·
Mar 13

ImmunityBio Coverage Assumed by BTIG at Buy

Dow Jones
·
Mar 12

U.S. RESEARCH ROUNDUP-AeroVironment, Bumble, Lumentum.

Reuters
·
Mar 12

ImmunityBio assumed with a Buy at BTIG

TIPRANKS
·
Mar 12

ImmunityBio Inc. publishes investor presentation on ANKTIVA bladder cancer program and global regulatory approvals

Reuters
·
Mar 11

Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Share Price Surge

Simply Wall St.
·
Mar 10

Moderately bullish activity in ImmunityBio with shares down 5.71%

TIPRANKS
·
Mar 10

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Mar 10

ImmunityBio Resubmits Supplemental Biologics License Application for Cancer Treatment Anktiva

MT Newswires Live
·
Mar 09

ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG

TIPRANKS
·
Mar 09

FDA acknowledges receipt of ImmunityBio’s resubmitted sBLA for ANKTIVA plus BCG in NMIBC papillary tumors

Reuters
·
Mar 09

Immunitybio Announces Resubmission of Supplemental Bla to the FDA for Anktiva® Plus Bcg in Bcg-Unresponsive Nmibc With Papillary Disease Following Agency Review of Additional Data

THOMSON REUTERS
·
Mar 09

Immunitybio Inc - Resubmits Sbla After FDA Requests Additional Data; No New Trials Required

THOMSON REUTERS
·
Mar 09

Immunitybio Inc: FDA Has Acknowledged Receipt of Resubmitted Filing

THOMSON REUTERS
·
Mar 09

Mixed options sentiment in ImmunityBio with shares down 10.25%

TIPRANKS
·
Mar 05

ImmunityBio price target raised to $12 from $7 at Piper Sandler

TIPRANKS
·
Mar 04

Stock Track | ImmunityBio Soars 5.11% After-Hours on Upcoming Business Update and FY2025 Financial Results Announcement

Stock Track
·
Feb 28

ImmunityBio Inc. Updates Financial Calendar

Reuters
·
Feb 27